Pharmaceutical Intermediates
- • Analgesics (57)
- • Anesthetics (52)
- • Anti-Addiction Agents (8)
- • Antibacterials (117)
- • Anticonvulsants (20)
- • Antidementia Agents (23)
- • Antidepressants (35)
- • Antiemetics (24)
- • Antifungals (24)
- • Antigout Agents (9)
- • Anti-inflammatory Agents (28)
- • Antimigraine Agents (21)
- • Antineoplastics (427)
- • Antiparasitics (11)
- • Antiparkinson Agents (28)
- • Antipsychotics (54)
- • Antispasticity Agents (12)
- • Antivirals (146)
- • Anxiolytics (16)
- • Blood Glucose Regulators (105)
- • Blood Products (61)
- • Cardiovascular Agents (179)
- • CNS Agents (22)
- • Dental and Oral Agents (8)
- • Dermatological Agents (19)
- • Electrolytes (15)
- • Gastrointestinal Agents (62)
- • Genetic/Enzyme Disorder (12)
- • Genitourinary Agents (47)
- • Immunological Agents (36)
- • Metabolic Bone Disease (6)
- • Ophthalmic Agents (343)
- • Respiratory Tract (51)
- • Skeletal Muscle Relaxants (5)
- • Sleep Disorder Agents (28)
- • Oled Material Intermediate (333)
- • Heterocyclic Compound (9764)
- • Bulk Drug Intermediates (17727)
Related News
Antidepressants
5-bromo-6-fluoro-2,3-dihydro-1H-inden-1-one
(866862-25-1)-
- / 99.00%
-
Industrial Grade / 99.00%
-
-
Industrial Grade / 99%
Request for quotation , get quotes from more suppliers.
-
-
Industrial Grade / 95%
-
-
Request for quotation , get quotes from more suppliers.
-
-
Industrial Grade / 99.0%
-
-
Request for quotation , get quotes from more suppliers.
-
Pharmaceutical Grade / 98%
-
Industrial Grade / 99%
-
Industrial Grade / 99%
-
Request for quotation , get quotes from more suppliers.
1,3-Dioxolane-4-methanol, 2,2-dimethyl-, 4-(2-aminobenzoate)
(4934-23-0)-
Industrial Grade / 99.0%
-
-
-
Industrial Grade / 99%
Request for quotation , get quotes from more suppliers.
Source Antidepressants Raw Materials by Region
More Information
Antidepressants are substances used to alleviate symptoms of depression, anxiety, and other mood disorders by regulating neurotransmitter activity in the brain. They are widely applied in pharmaceutical formulations, clinical treatments, and research aimed at improving mental health outcomes.
Key mechanisms of action for antidepressants include:
• Selective serotonin reuptake inhibitors (SSRIs) – increase serotonin levels in synaptic gaps to improve mood regulation.
• Serotonin-norepinephrine reuptake inhibitors (SNRIs) – enhance both serotonin and norepinephrine signaling to relieve depressive and anxiety symptoms.
• Tricyclic antidepressants (TCAs) – block reuptake of neurotransmitters, affecting multiple neural pathways.
• Monoamine oxidase inhibitors (MAOIs) – inhibit the enzyme that breaks down neurotransmitters like serotonin and dopamine.
Factors to consider when selecting antidepressant raw materials:
• Type of mood disorder – major depressive disorder, generalized anxiety disorder, bipolar depression, etc.
• Safety and tolerability – side effect profile, potential drug interactions, and patient-specific considerations.
• Formulation requirements – solubility, stability, and compatibility for tablets, capsules, or oral solutions.
• Regulatory compliance – adherence to pharmaceutical safety standards and clinical guidelines.
Common antidepressant raw materials include fluoxetine, sertraline, venlafaxine, amitriptyline, and moclobemide. They are typically supplied in powder or crystalline forms for use in oral solid dosage forms, capsules, or solutions. These agents are essential in both clinical treatment and pharmaceutical research of mood disorders.
Frequently Asked Questions
Antidepressants are medications primarily used to treat depression, anxiety disorders, and other mood-related conditions. They work by altering the levels of certain neurotransmitters in the brain—such as serotonin, norepinephrine, and dopamine—that regulate mood, sleep, and emotion. Common classes include SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), tricyclic antidepressants, and MAOIs (Monoamine Oxidase Inhibitors). Understanding their mechanism helps healthcare providers choose the most appropriate treatment for individual patients.
The most commonly prescribed antidepressants belong to the SSRI class, including fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro), due to their effectiveness and relatively mild side effect profiles. SNRIs like venlafaxine (Effexor) and duloxetine (Cymbalta) are also widely used, especially when SSRIs are ineffective. Tricyclic antidepressants and MAOIs are older classes typically reserved for treatment-resistant cases because of their more significant side effects and safety considerations.
Most antidepressants take 4 to 6 weeks to show noticeable therapeutic effects, although some patients may experience improvements in sleep or appetite within the first 1–2 weeks. It’s important to continue taking the medication as prescribed, even if immediate relief isn’t felt. Full benefits can sometimes take up to 8–12 weeks. Abrupt discontinuation can lead to withdrawal symptoms, so any dosage changes should be managed under medical supervision.
Common side effects of antidepressants vary by class but may include nausea, headache, insomnia, drowsiness, dry mouth, weight gain, and sexual dysfunction. SSRIs generally have fewer side effects compared to older antidepressants like tricyclics, which can cause constipation, blurred vision, and cardiovascular issues. Most side effects diminish over time as the body adjusts. Patients should consult a healthcare provider before stopping medication due to side effects.
Yes, antidepressants are frequently prescribed off-label for a range of conditions beyond major depressive disorder. These include generalized anxiety disorder (GAD), panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), chronic pain syndromes (like fibromyalgia or neuropathic pain), and even migraine prevention. Their broad neurochemical effects make them versatile tools in managing various neurological and psychiatric conditions under professional guidance.